| This week's sponsor is Premier Research. | | | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown More bad news for Vical as it abandons herpes vaccine program Alexion snags option to buy neurodegeneration startup Complement BridgeBio spins out ultrarare genetic disease company after acquiring enzyme from Alexion Soon-Shiong planning to take cancer vaccine subsidiary public: report BIO: Lightning round with Sarepta's Doug Ingram Editas commits $125M to Broad to secure source of genome editing inventions What’s in a tweet? Sanofi's viral Roseanne retort draws kudos, followers and flak Featured Story | | | Monday, June 11, 2018 The deluge of bad news reported by Vical just won’t let up. The biotech confirmed today it has abandoned its lead genital herpes vaccine program after a negative phase 2 trial, following in the footsteps of earlier cancer and cytomegalovirus candidates. |
|
|
| This week's sponsor is Catalent. | | | |
Top Stories Monday, June 11, 2018 Alexion has secured the option to acquire Dutch biotech Complement Pharma. The agreement will see Alexion work with Complement to take a C6 complement inhibitor through phase 1b and decide whether to pull the trigger on a takeover along the way. Monday, June 11, 2018 Through an agreement with Alexion Pharmaceuticals, BridgeBio Pharma acquired a synthetic enzyme replacement therapy for an ultrarare, fatal genetic disease that causes seizures in infants. A new spinout, Origin Biosciences, will handle development. Monday, June 11, 2018 Billionaire healthcare mogul Patrick Soon-Shiong hopes to take public later this year one of his companies that is spearheading development of a cocktail of biologics as a vaccine aimed at multiple facets of cancer, according to an interview with Reuters. Monday, June 11, 2018 At BIO, we chatted with Doug Ingram about Sarepta's pipeline, its latest hires and how the healthcare landscape must change to make way for gene therapies. Monday, June 11, 2018 Editas Medicine has committed up to $125 million in research funding to the Broad Institute. The deal gives Editas first refusal on genome editing inventions developed in the sponsored research. Monday, June 11, 2018 Sanofi scored plenty of attention with its Twitter pushback against actress Roseanne Barr, who blamed its sleep aid Ambien for her own racist post. But did that viral tweet boost Sanofi and the Ambien brand? Patient gurus and social media analysts have some answers. | This week's sponsor is cobra:bio. | | | Accelerating Protein Production Since 1995
Cobra’s maxXpress service uses UCOE technology enables rapid production of monoclonal antibodies (mAbs), recombinant proteins and biosimilars while ensuring efficient, stable expression. More... |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Innovation, Collaboration and Entrepreneurship in Drug Discovery June 28, 2018 | Cambridge, UK CBI’s 14th Annual Medical Device Compliance Congress (MDCC) June 14-15, 2018 | Chicago, IL Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 